Mark Lipphardt1, Johannes Mühlhausen1, Bernd Kitze2, Franz Heigl3, Erich Mauch4, Hans-Joachim Helms5, Gerhard A Müller1, Michael J Koziolek1. 1. Department of Nephrology and Rheumatology, Georg-August-University Göttingen, Germany. 2. Department of Neurology, Georg-August-University Göttingen, Germany. 3. Department of Neurology, Medical Healthcare Centre Kempten, Kempten-Allgäu, Germany. 4. Neurological Hospital Dietenbronn, Schwendi, Germany. 5. Department of Medical Statistics, Georg-August-University Göttingen, Göttingen, Germany.
Abstract
BACKGROUND: Plasma exchange (PE) and immunoadsorption (IA) are alternative treatments of steroid-refractory relapses of multiple sclerosis (MS) or neuromyelitis optica (NMO). METHODS: Adverse events and neurological follow-ups in 127 MS- (62 PE, 65 IA) and 13 NMO- (11 PE, 2 IA) patients were retrospectively analyzed. Response was defined by improvements in either expanded disability status scale (EDSS) by at least 1.0 or visual acuity (VA) to 0.5, confirmed after 3 and/or 6 months. RESULTS: Hundred and forty patients were included in safety analysis, 102 patients provided sufficient neurological follow-up-data. There were no significant differences between IA and PE in side effects (3.9% vs 3.6%, P = .96) or response-rate (P = .65). Responders showed significant lower age (P = .02) and earlier apheresis-initiation (P = .01). Subgroup-analysis confirmed significant lower age in patients with relapsing-remitting MS (RRMS) /clinical isolated syndrome (CIS). CONCLUSION: IA and PE seem equally safe and effective in steroid-resistant MS- or NMO-relapses. Early apheresis and low patient age are additional prognostic factors.
BACKGROUND: Plasma exchange (PE) and immunoadsorption (IA) are alternative treatments of steroid-refractory relapses of multiple sclerosis (MS) or neuromyelitis optica (NMO). METHODS: Adverse events and neurological follow-ups in 127 MS- (62 PE, 65 IA) and 13 NMO- (11 PE, 2 IA) patients were retrospectively analyzed. Response was defined by improvements in either expanded disability status scale (EDSS) by at least 1.0 or visual acuity (VA) to 0.5, confirmed after 3 and/or 6 months. RESULTS: Hundred and forty patients were included in safety analysis, 102 patients provided sufficient neurological follow-up-data. There were no significant differences between IA and PE in side effects (3.9% vs 3.6%, P = .96) or response-rate (P = .65). Responders showed significant lower age (P = .02) and earlier apheresis-initiation (P = .01). Subgroup-analysis confirmed significant lower age in patients with relapsing-remitting MS (RRMS) /clinical isolated syndrome (CIS). CONCLUSION: IA and PE seem equally safe and effective in steroid-resistant MS- or NMO-relapses. Early apheresis and low patient age are additional prognostic factors.
Authors: Karl Oettl; Andreas Kribben; Kristina Boss; Mark Stettner; Fabian Szepanowski; Anne K Mausberg; Margret Paar; Refik Pul; Christoph Kleinschnitz Journal: Sci Rep Date: 2022-07-16 Impact factor: 4.996
Authors: Nic Skorupka; Andrei Miclea; Katarzyna Aleksandra Jalowiec; Christoph Bocksrucker; Nicole Kamber; Andrew Chan; Behrouz Mansouri Taleghani; Robert Hoepner; Anke Salmen Journal: Transfus Med Hemother Date: 2019-11-14 Impact factor: 3.747
Authors: Tobias Moser; Gayane Harutyunyan; Anush Karamyan; Ferdinand Otto; Carola Bacher; Vaclav Chroust; Markus Leitinger; Helmut F Novak; Eugen Trinka; Johann Sellner Journal: Brain Sci Date: 2019-10-09
Authors: Johannes Dorst; Tanja Fangerau; Daniela Taranu; Pia Eichele; Jens Dreyhaupt; Sebastian Michels; Joachim Schuster; Albert C Ludolph; Makbule Senel; Hayrettin Tumani Journal: EClinicalMedicine Date: 2019-11-14